Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
120 participants
OBSERVATIONAL
2023-06-08
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with singleton pregnancies on our site with repeated ultrasound measurements every 4 weeks will be evaluated for fetal brain development. The exposed group is defined as patients with a dual exposure of TPTL and ACS. The non-exposed group will be composed of patients who did not have TPTL and ACS. Therefore, patients will have a maximum of 5 additional visits (4 that will occur prenatally and 1 postnatal visit).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Early and Severe Fetal Growth Restriction on Neurodevelopmental Outcomes in Preterm Infants
NCT05381272
Brainstem and Prematurity
NCT02669056
Diffusion-weighted Cerebral MRI and Intra Uterine Growth Restriction.
NCT02229630
Maternal Voice and Quantitative EEG (qEEG)
NCT05391633
Evaluation of Brain Volume and Dimensions in Healthy Fetuses Using Obstetrics Ultrasound Examination at 14-34 Weeks of Pregnancy.
NCT03186807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary Outcome: Our primary outcome will be the feasibility of a prospective observational study measuring fetal and neonatal brain growth using 2D and 3D ultrasound in fetuses exposed to TPTL and ACS to non-exposed fetuses. Feasibility will be defined on the following criteria: 1. Number of patients recruited per month; 2. Ability to recruit eligible patients and 3. Ability to successfully complete the 2D measures and 3D volumes for each ultrasound exam. Success will be defined by the following criteria: 1. At least two patients will be recruited per month; 2. At least 50% of all eligible patients exposed to TPTL and ACS will be recruited; 3. At least 50% of all 2D measures and 3D volumes could be obtained.
Secondary Outcomes: Our secondary outcomes will include 2D and 3D ultrasound measurements of fetal brain structures, more specifically: biparietal diameter, head circumference, corpus callosum length, corpus callosum-fastigium length, ventricular width, total fetal brain volume, frontal lobe volume, cerebellar volume, and thalamic volume (all measurements in cm). Neonatal brain structures will also be measured by 2D ultrasound, including corpus callosum length and corpus callosum-fastigium length (in cm).
Exposed patients will have a fetal ultrasound performed by a trained and qualified ultrasound technologist or a Maternal-Fetal Medicine specialist within 4 days of their admission to the hospital. Psychometric questionnaires will be filled on the same day. Ultrasounds will subsequently be performed at fixed gestational age: 24, 28, 32, and 36 weeks (+/- 4 days).
Non-exposed patients will have fetal ultrasound performed by a trained and qualified ultrasound technologist or a Maternal-Fetal Medicine specialist at 24, 28, 32, and 36 weeks (+/- 4 days). Psychometric questionnaires will be filled on each of those days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant women exposed to threatened preterm labor and exposed to antenatal corticosteroids
Pregnant women with threatened preterm labor (TPTL) who received antenatal corticosteroids (ACS) between 22 and 34 weeks and 6 days of gestation at our hospital.
No interventions assigned to this group
Non-exposed pregnant women
Pregnant women with normal pregnancies.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 22-34 weeks and 6 days gestation at time of recruitment.
* Threatened preterm labor (TPTL)
* Administration of a partial or full course of ACS.
* Admission to the MUHC-RVH birthing center or the antenatal floor (D6S).
* Delivery planned at the MUHC-RVH or an institution around the Greater Montreal Area.
Non-exposed group:
* At or prior to 22 weeks gestation at time of recruitment.
* Delivery planned at the MUHC-RVH.
Exclusion Criteria
* Significant maternal disease which may cause preterm delivery or fetal growth restriction (e.g., severe infection, uncontrolled hypertension or diabetes).
* Patients who received more than one course of ACS prior to enrollment.
* Patients on any oral or other systemic corticosteroids, with the exception of inhaled corticosteroids.
* BMI over 35.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
McGill University
OTHER
University of Arizona
OTHER
McGill University Health Centre/Research Institute of the McGill University Health Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jarred Garfinkle
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne-Maude Morency, MD
Role: PRINCIPAL_INVESTIGATOR
RI-MUHC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
McGill University Health Centre
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-8114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.